aptaTargets

We are excited to announce an agreement with @MerckHealthcare for the clinical development and commercialization of #ApTOLL, a Toll-like receptor 4 (TLR4) antagonist being developed for acute ischemic stroke. Learn more: aptatargets.com/newsroom/aptat… #healthcare #innovation

🌟 aptaTargets and @merckgroup named finalists in 2025 European @lifestarsawards for transfer of neuroprotective drug #ApTOLL 🌟 Learn more on our website: aptatargets.com/newsroom/aptat… #lifestarsawards

#ApTOLL’s secondary analysis data of APRIL 1b/2a trial published in scientific journal “Stroke” from @American_Heart: aptatargets.com/newsroom/aptol… #stroke #AcuteIschemicStroke #cerebroprotection

#Investigación | ➡️El emprendimiento en el ámbito biomédico va acompañado de algunas metas a superar específicas de este sector. ➡David Segarra, CEO de @AptaTargets, cuenta los obstáculos a superar en el escalado de la innovación en este sector. #Echobox=1752143584" target="_blank" rel="nofollow noopener">diariomedico.com/medicina/inves…

#Investigación | ➡️El emprendimiento en el ámbito biomédico va acompañado de algunas metas a superar específicas de este sector. ➡David Segarra, CEO de @AptaTargets, cuenta los obstáculos a superar en el escalado de la innovación en este sector. #Echobox=1752742631" target="_blank" rel="nofollow noopener">diariomedico.com/medicina/inves…

.@inveready has achieved a 4x return on its Innvierte Biotech II fund. Benchmark Spanish financial newspaper @expansioncom highlights aptaTargets among its top investments. aptaTargets recently transferred its drug #ApTOLL to @merckgroup.

.@AptaTargets has announced an agreement with German pharmaceutical giant @Merck for the clinical development and commercialisation of ApTOLL, a TLR4 antagonist being developed to treat acute ischaemic #Stroke neuronewsinternational.com/merck-assumes-…

.@AptaTargets transfiere ApTOLL a Merck biotech-spain.com/es/articles/ap…

#Industria | aptaTargets transfiere ApTOLL a Merck 📰 tinyurl.com/yv9dsuap @AptaTargets @merck_es

⚕️Today on #WorldHealthDay, we're highlighting three top #eicBAS beneficiaries driving better #HealthForAll and #HopefulFutures globally: 💡 @SymphysisMed 🧠 @AptaTargets 🩺 Better Medicine Check them out 👉 tinyurl.com/yntdfexc

A new study shows the cerebroprotective effects of #ApTOLL on mice with #AcuteIschemicStroke: bit.ly/3yR1ZAX The study, published in "Pharmaceutics" (@MDPIpharma), was conducted by researchers at aptaTargets (Dr. Macarena Hernández) and @IISLaFe (Dr. Juan Salom).

Preclinical studies validate the potential of #ApTOLL developed by aptaTargets to reduce inflammation and regenerate myelin in models of #MultipleSclerosis. Results published in @BrJPharmacol: bit.ly/3WPkbF4

Today our Clinical Operations Manager @MarcoPugliese7 will speak at "Creative strategies to accelerate patient recruitment rate during study planning" in Barcelona. With Alicia Rami @Fortrea, @Estrell67715016 (Almirall), Núria Bordas @ferrerforgood and Joseph Lovett @Medidata 👇🏼

There's still time to register for #ESOC2024 in Basel, starting in just a week! 📅 ow.ly/7im650RuF4V Get ready to hear from leading experts, engage in innovative discussions, and be part of the latest advancements in stroke research. #stroke #voiceofstroke #stroketwitter

Our CSO Macarena Hernández (@makimhj) will speak at the 10th European #Stroke Conference next May 15 in Basel. Join us to discover “Tackling the Inflammation: The #APRIL group”. 🕓 3:50 pm 📍 Basel - Room Boston ℹ️ bit.ly/44tCnpm #ESOC2024 #ApTOLL #cytoprotection

We are thrilled to announce that over 1,000 companies in Europe, aptaTargets was selected for the #EICAccelerator by @EUeic. It secures €2.5M grant to start the Phase 2b clinical trial with #ApTOLL in patients with #AcuteIschemicStroke: bit.ly/3v5tg0O

Proximo miercoles en el @USPCEU hablaré sobre los #aptameros y sus aplicaciones. Desde @AptaTargets trabajamos en el consorcio @oligofastx en el tratamiento de #EnfermedadesRaras como el Síndrome de Guillain-Barré

El próximo miércoles 6 de marzo recibiremos a Miguel Moreno Molina, de @AptaTargets, en nuestros seminarios de la @USPCEU . Conoceremos los últimos avances en tecnología de aptámeros. Bienvenido!

aptaTargets, that has obtained the Seal of Excellence 🏅 from the #EICAccelerator, has been selected by the @ComunidadMadrid to receive a direct grant of €1.940M: bit.ly/3UJI4N0 #ApTOLL #neuroprotection #AcuteIschemicStroke #EUeic #HorizonEurope #NextGenerationEU

🧪 #OLIGOFASTX has the leading experts in each field in the area of oligonucleotide research who can provide solutions in the research of new therapies against rare diseases. 🧬 📌 oligofastx.com #fundedbyCDTI